Trametinib: A Breakthrough Treatment for Low-Grade Serous Ovarian Cancer

Trametinib is changing the treatment landscape for women with low-grade serous ovarian cancer, offering new hope where traditional chemotherapy often falls short.

If you’ve been diagnosed with low-grade serous ovarian cancer (LGSOC) and you’re researching treatment options, you’ve probably noticed something frustrating: most ovarian cancer information focuses on the high-grade form of the disease. That’s because LGSOC is rare, accounting for only about 5% of all epithelial ovarian cancers. 

But here’s what makes this cancer different. LGSOC typically affects younger women — often in their 40s rather than their 60s. It grows more slowly than high-grade disease. And critically, it doesn’t respond well to the standard platinum-based chemotherapy that works for other ovarian cancers.

That’s where trametinib comes in.

What Is Trametinib and How Does It Work?

Trametinib (brand name Mekinist) is a targeted therapy — a type of drug that attacks specific proteins involved in cancer growth rather than broadly targeting all rapidly dividing cells like traditional chemotherapy does.

Here’s how trametinib works: It blocks proteins called MEK1 and MEK2, which act like an “on switch” for cancer growth. These proteins are part of the MAPK signaling pathway, which controls how cells grow and divide. Think of trametinib as a roadblock in a long chain of signals that tell cancer cells to keep growing.

What makes trametinib unique is its mechanism of action. Unlike most kinase inhibitors that compete for the same ATP binding site, trametinib uses something called allosteric inhibition — it binds to a spot adjacent to the ATP binding site. This means it doesn’t need to compete with ATP, which contributes to its high selectivity and effectiveness even at low concentrations.

In low-grade serous ovarian cancer, this pathway is often overactive due to genetic mutations, particularly in genes called KRAS, BRAF, and NRAS.

About half of all LGSOC tumors have mutations that rev up this pathway. By blocking MEK proteins, trametinib essentially puts the brakes on cancer cell growth.

The drug was originally approved for treating certain melanomas, lung cancers, and thyroid cancers with specific BRAF mutations. But researchers saw promise for LGSOC patients because of the similar pathway involvement.

The Landmark Trial That Changed Everything

The GOG 281/LOGS trial was the first positive randomized clinical trial showing that trametinib represents a new standard-of-care option for LGSOC patients. 

This international study, led by Dr. David Gershenson at MD Anderson Cancer Center and conducted across 84 hospitals in the US and UK, enrolled 260 women with recurrent low-grade serous ovarian cancer. 

Half received trametinib (2 mg daily pill). The other half received one of five standard treatments: chemotherapy drugs (paclitaxel, pegylated liposomal doxorubicin, or topotecan) or hormone therapies (letrozole or tamoxifen).

The results were striking:

• Median progression-free survival was 13 months with trametinib versus only 7.2 months with standard care, meaning trametinib reduced the risk of disease progression or death by 52%.
• Response rate was 26% with trametinib compared to just 6% with standard treatments.
• Median duration of response was 13.6 months with trametinib versus 5.9 months with standard care.

Even patients in the standard-care group who crossed over to trametinib after their cancer progressed saw benefit. Of those patients, 65% had a longer time to disease progression on trametinib than they’d had on their previous therapy.

Do You Need to Have a Specific Mutation to Benefit?

Here’s something important: you might benefit from trametinib even if you don’t have a KRAS, BRAF, or NRAS mutation.

In the GOG 281 trial, only 33% of tested patients had these mutations. Yet trametinib showed benefit regardless of mutation status. Patients without these mutations still experienced improved progression-free survival compared to standard care.

That said, patients with KRAS, BRAF, or NRAS mutations appeared to have even better results—with a 50% response rate versus 8.3% in those without these mutations.

The takeaway? Trametinib should be considered for all women with LGSOC recurrence, whether or not genetic testing reveals these specific mutations. The National Comprehensive Cancer Network (NCCN) guidelines list trametinib as “useful in certain circumstances” for LGSOC in the recurrent setting — both platinum-sensitive and platinum-resistant disease — without requiring specific biomarker testing.

However, it’s important to know that trametinib remains “off-label” for LGSOC, meaning it hasn’t received FDA approval specifically for this indication. While the NCCN listing typically helps with insurance coverage, some insurers may still require prior authorization or additional documentation. Talk to your oncology team’s financial counselor about coverage before starting treatment.

If you’re considering trametinib, it’s still worth having genetic testing for LGSOC done through your treatment team. Understanding your tumor’s specific mutations can help guide future treatment decisions and may qualify you for LGSOC clinical trials.

Trametinib Side Effects: What to Expect

Let’s be honest about the trametinib side effects. They’re real, and they can be challenging. But they’re also manageable, especially with an oncology team experienced in using MEK inhibitors.

The most common serious side effects in the trial were:

• Skin rash (13% experienced grade 3 or higher)
• Anemia or low red blood cell counts (13%)
• High blood pressure (12%)
• Diarrhea (10%)
• Nausea (9%)
• Fatigue (8%)

Other less common but important side effects include:

• Decreased heart ejection fraction (8% of patients)
• Vision changes or retinal problems
• Pneumonitis (lung inflammation)
• Blood clots
• Skin infections

The good news? Most side effects are treatable. Skin rashes can be managed with topical treatments and oral antibiotics like doxycycline. Diarrhea, nausea, and fatigue can often be controlled with supportive medications. And if side effects become too severe, your dose can be reduced or temporarily stopped.

Trametinib Cost and Access

Let’s address the elephant in the room: trametinib cost.

Trametinib is not inexpensive. The drug was developed by Novartis and is currently approved for melanoma, lung cancer, and thyroid cancer with specific BRAF mutations. Its use for ovarian cancer is considered “off-label” in the United States.

However, after the GOG 281 trial results were presented in 2019, trametinib was added to the National Comprehensive Cancer Network (NCCN) compendium for low-grade serous ovarian cancer. This listing typically allows most patients to get insurance coverage, at least in the United States.

The good news: many patients pay little to nothing out of pocket. Specialty pharmacies that handle trametinib often have financial assistance programs that can reduce or eliminate copays, particularly for Medicare and Medicaid patients. Some patients qualify for $0 copay through manufacturer assistance programs. Additionally, trametinib is available through discount services like GoodRx, which can significantly lower costs for those paying out of pocket.

In the United Kingdom, NHS England issued a clinical commissioning policy in November 2023 making trametinib available as a routine treatment option for adults with recurrent or progressive LGSOC (source: NHS England Clinical Commissioning Policy).

If you’re concerned about cost:

• Talk to your oncology team’s financial counselor about insurance coverage
• Ask about patient assistance programs from the manufacturer
• Work with a specialty pharmacy that can help secure copay assistance, as many patients qualify for zero out-of-pocket costs
• Check GoodRx or similar discount programs if paying without insurance
• Inquire whether your treatment center has grant programs or charity care options
• Consider enrolling in clinical trials, which often cover medication costs

For additional support navigating cancer costs, explore “Ovarian Cancer Treatment Cost: Making Cancer Care More Affordable.”

Who Should Consider Trametinib?

Based on the trial results and current guidelines, trametinib should be considered for:

• Women with recurrent or progressive low-grade serous ovarian cancer
• Those who have received at least one prior platinum-based chemotherapy regimen
• Patients with good performance status (able to care for themselves and carry out daily activities)

Trametinib should be stopped if:

• Your cancer progresses despite treatment
• You experience unacceptable side effects that can’t be managed
• You choose to discontinue treatment

What’s Next for Trametinib and LGSOC Research?

The success of the GOG 281 trial has opened doors for additional research.

Researchers are now exploring:

• Combination therapies: Studies testing trametinib plus hormone therapy (like aromatase inhibitors) or other targeted drugs
• Biomarker refinement: Work to better identify which patients will benefit most
• Earlier use: Trials examining trametinib as initial treatment rather than waiting for recurrence
• Resistance mechanisms: Understanding why some patients don’t respond or eventually progress on trametinib

The Bottom Line on Trametinib

Trametinib represents one of the first targeted therapies proven to work specifically for low-grade serous ovarian cancer. It’s not a cure, and it comes with manageable but real side effects. But for women with LGSOC, particularly recurrent disease that hasn’t responded to other treatments, it offers something invaluable: time.

If you have LGSOC and you’re facing recurrence or progression, ask your oncologist whether trametinib might be right for you.